Abstract: Disclosed is a device and method for preparing composite ice glaze, relating to the field of freshness of aquatic products. The device includes a frame portion, a mother liquid preparation portion, an ice glaze preparation portion, an ice glaze post-processing portion and a controller system; the frame portion includes a shell, a base, and a thermal insulation baffles; the mother liquid preparation portion includes a main water inlet pipe, a water storage tank, mother liquid tanks; the ice glaze preparation portion includes a homogenizing tank, a homogenizing tank inlet pipe, a waste cylinder inlet pipe; the ice glaze post-processing portion includes a reception cylinder, and a waste cylinder. The device provided by the invention is simple to use, and the prepared concentration is accurate and effective, so that the compounding process can be simplified and the compounding efficiency is effectively improved.

Abstract: Disclosed herein is a live attenuated recombinant measles virus (rMeV)-based coronavirus vaccine containing a SARS-CoV-2 spike (S) protein that has at least one mutation to remove a glycosylation site. In some embodiments, the rMeVs-based coronavirus vaccine contains full-length stabilized pre-fusion and native S proteins, S proteins of SARS-CoV-2 variants, truncated S proteins lacking its transmembrane and cytoplasmic domains, S proteins lacking glycosylation sites, the monomeric and trimeric receptor-binding domain (RBD), the monomeric and trimeric S1 protein, Fc-fused RBD, or Fc-fused S1 protein. Also disclosed is a live attenuated recombinant coronavirus vaccine, wherein a stabilized prefusion spike (S) protein is inserted into a viral vector genome.

Abstract: Embodiments disclosed herein provide compositions, methods, and uses for recombinant vectors encoding Zika virus (ZIKV) protein subunits, and immunogenic compositions thereof. Certain embodiments provide recombinant vectors encoding ZIKV nonstructural protein 1 (NS 1), and optionally, ZIKV envelope (E) protein and premembrane (prM) protein. Other embodiments provide expression cassettes comprising a promoter operably linked to a polynucleotide that encodes the ZIKV NS 1 protein, and optionally ZIKV E and prM proteins. In some embodiments, the disclosed expression cassettes can be incorporated into a vector to produce a recombinant vector. Also provided are immunogenic compositions comprising one or more recombinant vectors described herein, and methods for inducing an immune response against ZIKV in a subject comprising administering to the subject an immunologically effective dose of an immunogenic composition of the present disclosure.

Abstract: The present disclosure provides a preparation method of a surimi low-molecular-weight antifreeze peptide, and relates to the technical field of processing of aquatic products. The preparation method includes the following steps: step 1, with Larimichthys crocea as a raw material, decapitating and gutting the L. crocea, crushing the L. crocea into a surimi, decalcifying the surimi, extracting water-soluble crude protein with water, and freeze-drying to obtain the water-extracted crude protein powder of L. crocea; step 2, redissolving the water-extracted crude protein powder of L. crocea obtained in step 1 with water, and enzymatically hydrolyzing it with protease to obtain an enzymatic hydrolysate; and step 3, sonicating and dialyzing the enzymatic hydrolysate obtained in step 2 to obtain a dialysate with a molecular weight no more than 3,500 D, and freeze-drying the dialysate to obtain the surimi low-molecular-weight antifreeze peptide.

Abstract: Disclosed is a dynamic demonstration method for water-soluble ion concentration and components of an aerosol. The method comprises: obtaining concentration data of each ion in an atmospheric aerosol of a target city in a preset time period and filling the concentration data in a data table; obtaining vertex coordinates of each ion in a Maucha graph according to equivalent concentration data of each ion; drawing an aerosol ion Maucha graph of the target city in each preset time period according to the vertex coordinates; and finally making a dynamic picture according to a temporal graph of aerosol ion concentration in various time periods.

Abstract: Disclosed is a dynamic demonstration method for water-soluble ion concentration and components of an aerosol. The method comprises: obtaining concentration data of each ion in an atmospheric aerosol of a target city in a preset time period and filling the concentration data in a data table; obtaining vertex coordinates of each ion in a Maucha graph according to equivalent concentration data of each ion; drawing an aerosol ion Maucha graph of the target city in each preset time period according to the vertex coordinates; and finally making a dynamic picture according to a temporal graph of aerosol ion concentration in various time periods.

Abstract: The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.

Abstract: The present invention provides a virulent Pseudomonas fluorescens (P. fluorescens) phage ?Pf1901, and a phage ?Pf1901 preparation and an application thereof, and relates to the technical field of phage. The virulent P. fluorescens phage ?Pf1901 has an accession number of CCTCC M2019447. The virulent phage ?Pf1901 has a titer of (1.4-3)×1010 PFU/mL. The virulent phage ?Pf1901 has an optimal multiplicity of infection (MOI) value of 0.0001. The virulent P. fluorescens phage ?Pf1901 provided by the present invention exhibits very high specificity and lytic ability to P. fluorescens, which can be used to control P. fluorescens, with strong lytic and scavenging effects on a host.

Abstract: Embodiments disclosed herein provide compositions, methods, and uses for recombinant vectors encoding Zika virus (ZIKV) protein subunits, and immunogenic compositions thereof. Certain embodiments provide recombinant vectors encoding ZIKV nonstructural protein 1 (NS 1), and optionally, ZIKV envelope (E) protein and premembrane (prM) protein. Other embodiments provide expression cassettes comprising a promoter operably linked to a polynucleotide that encodes the ZIKV NS 1 protein, and optionally ZIKV E and prM proteins. In some embodiments, the disclosed expression cassettes can be incorporated into a vector to produce a recombinant vector. Also provided are immunogenic compositions comprising one or more recombinant vectors described herein, and methods for inducing an immune response against ZIKV in a subject comprising administering to the subject an immunologically effective dose of an immunogenic composition of the present disclosure.

Abstract: The present invention provides a virulent Pseudomonas fluorescens (P. fluorescens) phage ?Pf1901, and a phage ?Pf1901 preparation and an application thereof, and relates to the technical field of phage. The virulent P. fluorescens phage ?Pf1901 has an accession number of CCTCC M2019447. The virulent phage ?Pf1901 has a titer of (1.4?3)×1010 PFU/mL. The virulent phage ?Pf1901 has an optimal multiplicity of infection (MOI) value of 0.0001. The virulent P. fluorescens phage ?Pf1901 provided by the present invention exhibits very high specificity and lytic ability to P. fluorescens, which can be used to control P. fluorescens, with strong lytic and scavenging effects on a host.

Abstract: Disclosed herein are vaccines, immunogenic compositions, and methods of using the same to treat and prevent respiratory syncytial virus (RSV). Specifically, disclosed are immunogenic compositions wherein a protein or immunogenic fragment of RSV is delivered to a subject in a recombinant viral vector platform, such as vesicular stomatis virus (rVSV).

Abstract: Disclosed is a device and method for preparing composite ice glaze, relating to the field of freshness of aquatic products. The device includes a frame portion, a mother liquid preparation portion, an ice glaze preparation portion, an ice glaze post-processing portion and a controller system; the frame portion includes a shell, a base, and a thermal insulation baffles; the mother liquid preparation portion includes a main water inlet pipe, a water storage tank, mother liquid tanks; the ice glaze preparation portion includes a homogenizing tank, a homogenizing tank inlet pipe, a waste cylinder inlet pipe; the ice glaze post-processing portion includes a reception cylinder, and a waste cylinder. The device provided by the invention is simple to use, and the prepared concentration is accurate and effective, so that the compounding process can be simplified and the compounding efficiency is effectively improved.

Abstract: Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed.

Abstract: A method of providing services for a messaging application with in-built web search is performed by an internet server. The internet server receives a query request from the messaging application of a first user device and then processes the query request. Processing the query request includes communicating with one or more internet services to obtain query results. The internet server generates an encoded message that includes a reference to the query results and maintains a database that correlates the reference with the query results. The internet server then forwards a query response, including the query results and the encoded message, to the first user device. The reference to the query results are subsequently received at the internet server from a second user device. The internet server forwards the one or more query results to the second user device based on the received reference.

Abstract: The present invention provides compositions useful to induce immune response to human metapneumovirus. Also provided are related materials and methods, including methods to induce an immune response in a mammal, comprising administering the compositions herein.

Abstract: Described herein are mutant pneumoviruses comprising a nucleotide sequence which encodes a mutated zinc binding motif in an M2-1 protein of the pneumovirus, wherein the zinc binding motif is mutated relative to wild-type pneumovirus. The mutant pneumoviruses described herein grow to high titer in cell culture, are genetically stable, are attenuated in vitro and in vivo, and are highly immunogenic. Also described herein are vaccines and vaccine compositions comprising the live attenuated mutant pneumoviruses. Vaccine compositions can further comprise a pharmaceutically acceptable carrier, vehicle, excipient, and/or adjuvant. Methods for inducing a protective immune response in a subject against a pneumovirus infection are also described and disclosed.

Abstract: Described herein are methyltransferase (MTase)-defective recombinant viruses as vaccines for human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and human parainfluenza virus type 3 (PIV3); as well as related materials and methods.

Abstract: The present invention includes methyltransferase (MTase)-defective recombinant viruses as live vaccine candidates for human metapneumovirus (hMPV), human respiratory syncytial virus (hRSV), and human parainfluenza virus type 3 (PIV3). Here the inventors provide the technical description for generating MTase-defective paramyxoviruses useful as immunogens, as well as related materials and methods.

Abstract: The inventors have successfully developed a recombinant vesicular stomatitis virus which expresses the major capsid protein of human norovirus. Infection of mammalian cells with the recombinant vesicular stomatitis virus resulted in production of high level of human norovirus virus-like particles. Importantly, the inventors further demonstrated that recombinant vesicular stomatitis virus expressing the major capsid protein of human norovirus displayed attenuated virulence in mice and elicited a high level of human norovirus-specific humoral, cellular, and mucosal immune responses in mice model. Therefore, norovirus-immunogenic compositions are herein provided, as are materials and methods useful to make and use the compositions.